Krueger J G, Segal R A, Moyer R C
Cancer Res. 1977 Jan;37(1):320-2.
The blastogenic response of normal spleen, lymph node, and peripheral blood lymphoid cells to tumor-associated antigens (TAA) derived from two syngeneic C57BL/6J tumors was measured by [3H]thymidine incorporation. Peripheral blood cells were responsive to TAA from B16 melanoma and from BW10232 mammary carcinoma at both a high (10(-1) to 10(-3) mg/ml) and a low (10(-5) to 10(-6) mg/ml) concentration of antigen. While peripheral blood cells always responded to TAA, spleen cells and lymph node cells did not. When spleen and lymph node cells did respond, they sometimes responded at different concentrations of TAA than did the peripheral blood cells. Spleen cells generally responded to "low" concentrations of TAA, while lymph node cells responded to "high" concentrati-ns of TAA. These data suggest two subpopulations of lymphoid cells capable of response to TA.. Spleen cells from mice bearing the BW10232 mammary carcinoma became responsive to BW10232 TAA at low concentrations of antigen. Lymph node cells became responsive at high concentrations of BW10232 antigen. The response of both subpopulations to BW10232 TAA was amplified in peripheral blood cells. Spleen cells were 30 times more responsive in the tumor bearer than in normal animals, while lymph node cells were only 3 times more responsive. It is shown that lymphoid cells taken from different areas or "lymphoid compartments" do not always show similar responses and should not be considered equivalent in evaluating immune responses to tumor cells.
通过[3H]胸腺嘧啶核苷掺入法,测定了正常脾脏、淋巴结和外周血淋巴细胞对源自两种同基因C57BL/6J肿瘤的肿瘤相关抗原(TAA)的增殖反应。外周血细胞在高浓度(10^(-1)至10^(-3)mg/ml)和低浓度(10^(-5)至10^(-6)mg/ml)抗原条件下,均对来自B16黑色素瘤和BW10232乳腺癌的TAA有反应。虽然外周血细胞总是对TAA有反应,但脾细胞和淋巴结细胞则不然。当脾细胞和淋巴结细胞确实有反应时,它们有时对TAA的反应浓度与外周血细胞不同。脾细胞通常对“低”浓度的TAA有反应,而淋巴结细胞对“高”浓度的TAA有反应。这些数据表明存在两个能够对TAA作出反应的淋巴细胞亚群。携带BW10232乳腺癌的小鼠的脾细胞在低浓度抗原条件下对BW10232 TAA变得有反应。淋巴结细胞在高浓度的BW10232抗原条件下有反应。这两个亚群对外周血细胞中BW10232 TAA的反应均得到增强。荷瘤小鼠的脾细胞反应性比正常动物高30倍,而淋巴结细胞仅高3倍。结果表明,取自不同区域或“淋巴区室”的淋巴细胞并不总是表现出相似的反应,在评估对肿瘤细胞的免疫反应时不应被视为等同。